Nymox Pharmaceutical Corp (NYMXF)
NYMXF is quoted over the counter, not listed on an exchange. Nymox Pharmaceutical Corp files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | NYMXF, quoted over the counter |
| SEC CIK | 0001018735 |
| OTC Markets tier | OTCID (price source, 2026-11-13) |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Business address | Quebec Canada, QC |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Considering recent developments and the need for additional financing, there exists a material uncertainty that casts substantial doubt about the Corporation's ability to continue as a going concern." | 20-F 2026-09-14 |
| Cash and burn | $830K cash; operating cash flow -$650K a quarter. | Report 2024-12-31 |
| Shares outstanding | 102,040,140 (2025-12-31); 94,540,140 a year earlier; 90,515,140 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | M&K CPAS, PLLC, The Woodlands, Texas, United States | PCAOB Form AP 2026-09-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2024 2024-12-31 | Not filed | -$4.5M | -$2.6M | Not filed | No debt tags | Needs four quarters | 20-F 2025-06-03 |
| FY 2023 2023-12-31 | $0 | -$8.8M | -$4.1M | Not filed | No debt tags | $0 | 20-F 2025-06-03 |
| FY 2022 2022-12-31 | $0 | -$6.6M | -$5.2M | Not filed | No debt tags | $0 | 20-F 2025-06-03 |
| FY 2021 2021-12-31 | $0 | -$12.5M | -$9.8M | $830K | No debt tags | $0 | 20-F 2024-08-29 |
| FY 2020 2020-12-31 | $5K | -$11.7M | -$10.0M | $3.6M | No debt tags | $5K | 20-F 2023-05-02 |
| FY 2019 2019-12-31 | $116K | -$13.2M | -$7.4M | $5.2M | No debt tags | $116K | 20-F 2022-03-30 |
| FY 2018 2018-12-31 | $299K | -$10.6M | -$7.8M | $7.9M | No debt tags | $299K | 20-F 2021-03-29 |
| FY 2017 2017-12-31 | $224K | -$13.4M | -$6.2M | $851K | No debt tags | $224K | 20-F 2020-03-30 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2022-03-29 |
| Latest annual report | 20-F | 2026-09-14 |
| Latest quarterly / interim | 6-K | 2026-08-31 |
Source: SEC EDGAR submissions feed, 408 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier